# Usana Health Sciences Inc.

**USNA**

NYSE; healthcare; SIC 2833, Medicinal Chemicals & Botanical Products; CIK 0000896264

**B**

**second fifth of 305 graded peers in healthcare**

rank 103 of 305; percentile 33.6; sampling error 2.8 points; lower is stronger

A B C D E


**B, the elk**



## Scoreboard


| | |
|---|---|
| **Profitability** | B<br>percentile 32.4 |
| **Solvency** | B/C<br>percentile 41.4 |
| **Growth and financing** | C<br>percentile 55.4 |
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $742.9M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress, fortress balance sheet |
| **Inputs computable** | 10 of 13 |
| **Graded from** | filings received through Mar 16, 2026<br>251 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026 |
| **Last close** | $12.95<br>2026-11-20; market equity $239.3M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 16, 2026*

," and Part II, "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" of this report, as well as in the other filings we make from time to time with the SEC, in evaluating us, our business and an investment in our securities. Below is a summary of the principal factors that make an investment in the common stock of the Company risky or speculative. This summary does not address all of the risks we face. Unless otherwise indicated or otherwise required by the context, the terms "we," "our," "it," "its," "Company," and "USANA" refer to USANA Health Sciences, Inc. and its wholly owned subsidiaries.

## The thirteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*


| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 32.4** | | | | | | |
| Gross profitability | 97.5% | 32.8% | | 3.2 | 346 | 2026-01-03 |
| Return on invested capital | not computable | 9.6% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (1.6%) | (6.7%) | 78.0 | 756 | 2026-01-03 |
| Gross margin stability, five years | 1.2 pts | 2.8 pts | 16.1 | 237 | 2026-01-03 |
| **Solvency, sleeve percentile 41.4** | | | | | |
| Altman Z double-prime | 7.37 | 0.31 | 13.5 | 705 | 2026-01-03 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (3.61x) | | | |
| *latest aligned inputs end 2023-12-30; latest annual assets end 2026-01-03* | | | | | |
| Current ratio | 2.24x | 2.68x | 69.4 | 781 | 2026-01-03 |
| **Growth and financing, sleeve percentile 55.4** | | | | | |
| Revenue growth, three-year compound | (2.5%) | 9.6% | 77.4 | 400 | 2026-01-03 |
| Free cash flow growth, three-year compound | (55.0%) | 11.1% | 97.8 | 94 | 2026-01-03 |
| Reinvestment rate | 14.9% | 33.9% | 60.0 | 101 | 2026-01-03 |
| Asset growth, three years | 7.6% | 3.2% | 35.6 | 663 | 2026-01-03 |
| Net share issuance, one year | (2.4%) | 1.6% | 6.2 | 626 | 2026-03-13 |

## Among 305 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 98 | Sarepta Therapeutics, Inc. (SRPT) | 31.9 | B | |
| 99 | Amphastar Pharmaceuticals, Inc. (AMPH) | 32.2 | B | |
| 100 | Staar Surgical Co. (STAA) | 32.6 | B | |
| 101 | Arcutis Biotherapeutics, Inc. (ARQT) | 32.9 | B | |
| 102 | Stryker Corp. (SYK) | 33.2 | B | |
| 103 | Usana Health Sciences Inc. (USNA) | 33.6 | B | |
| 104 | Collegium Pharmaceutical, Inc. (COLL) | 33.9 | B | fortress balance sheet |
| 105 | Puma Biotechnology, Inc. (PBYI) | 34.2 | B | fortress balance sheet |
| 106 | Chemed Corp. (CHE) | 34.5 | B | |
| 107 | Tandem Diabetes Care Inc. (TNDM) | 34.9 | B | |
| 108 | CVRx, Inc. (CVRX) | 35.2 | B | |

## What the price implies

*at the 2026-11-20 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (31.6%) | (1.7%) | 28 |
| Distance from 52-week high | (44.3%) | (33.0%) | 40 |
| EBIT to enterprise value | not computable | 0.5% | |
| Free cash flow yield | 3.6% | 0.6% | 67 |
| Book value to price | 2.20 | 0.29 | 94 |
| Sales to price | 3.87 | 0.38 | 95 |
| Composite equity issuance, five years | (12.0%) | 13.5% | 16 |
| Relative strength against the sector, log excess return | (0.55) | (0.19) | 28 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | |
|---|---|---|
| Twelve-month failure probability, CHS model | not computable | 0.06% |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2026-01-03** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | pass |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $178.9M |
| Operating cash flow, four quarters | $41.7M |
| Months of runway | not finite |
| Days since last periodic filing | 10 (10-Q received Nov 12, 2026) |
| Median daily dollar volume, 63 sessions | $2.5M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $724.4M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 2 | assets | us-gaap:Assets | $742.9M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 3 | net income | us-gaap:NetIncomeLoss | $10.8M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 4 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $22.3M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 5 | assets | us-gaap:Assets | $748.2M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 6 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $925.3M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 7 | gross profit | us-gaap:GrossProfit | $693.3M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 8 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $854.5M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 9 | gross profit | us-gaap:GrossProfit | $744.3M | 2023-12-30 | 2026-03-16 | 10-K | 26-000021 |
| 10 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $921.0M | 2023-12-30 | 2026-03-16 | 10-K | 26-000021 |
| 11 | gross profit | us-gaap:GrossProfit | $804.7M | 2022-12-31 | 2025-03-12 | 10-K | 25-000092 |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $998.6M | 2022-12-31 | 2025-03-12 | 10-K | 25-000092 |
| 13 | gross profit | us-gaap:GrossProfit | $968.6M | 2022-01-01 | 2024-02-27 | 10-K | 24-000093 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.2B | 2022-01-01 | 2024-02-27 | 10-K | 24-000093 |
| 15 | current assets | us-gaap:AssetsCurrent | $288.4M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 16 | current liabilities | us-gaap:LiabilitiesCurrent | $128.6M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 17 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $465.7M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | $37.4M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 19 | book equity | us-gaap:StockholdersEquity | $533.1M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 20 | liabilities | us-gaap:Liabilities | $156.6M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 21 | operating income | us-gaap:OperatingIncomeLoss | $93.1M | 2023-12-30 | 2026-03-16 | 10-K | 26-000021 |
| 22 | interest expense | us-gaap:InterestExpense | $262,000 | 2023-12-30 | 2024-02-27 | 10-K | 24-000093 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $13.8M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $61.0M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $10.1M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $70.6M | 2023-12-30 | 2026-03-16 | 10-K | 26-000021 |
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $14.5M | 2023-12-30 | 2026-03-16 | 10-K | 26-000021 |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | $103.9M | 2022-12-31 | 2025-03-12 | 10-K | 25-000092 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $10.4M | 2022-12-31 | 2025-03-12 | 10-K | 25-000092 |
| 30 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $32.6M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 31 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $41.5M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 32 | income tax | us-gaap:IncomeTaxExpenseBenefit | $30.1M | 2026-01-03 | 2026-03-16 | 10-K | 26-000021 |
| 33 | current assets | us-gaap:AssetsCurrent | $279.2M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 34 | current liabilities | us-gaap:LiabilitiesCurrent | $139.6M | 2024-12-28 | 2026-03-16 | 10-K | 26-000021 |
| 35 | assets | us-gaap:Assets | $632.8M | 2023-12-30 | 2025-03-12 | 10-K | 25-000092 |
| 36 | assets | us-gaap:Assets | $596.5M | 2022-12-31 | 2024-02-27 | 10-K | 24-000093 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 18,456,935 | 2026-03-13 | 2026-03-16 | 10-K | 26-000021 |
| 38 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 18,904,526 | 2025-03-07 | 2025-03-12 | 10-K | 25-000092 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.